---
title: "RLMD.US (RLMD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RLMD.US/news.md"
symbol: "RLMD.US"
name: "RLMD.US"
parent: "https://longbridge.com/en/quote/RLMD.US.md"
datetime: "2026-06-13T23:23:01.854Z"
locales:
  - [en](https://longbridge.com/en/quote/RLMD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLMD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLMD.US/news.md)
---

# RLMD.US (RLMD.US) — Related News

### [Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session](https://longbridge.com/en/news/288579963.md)
*2026-06-03T12:29:50.000Z*
> U.S. stock futures surged over 7% on Wednesday, driven by AI optimism. Marvell Technology shares jumped 11.73% to $324.9

### [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://longbridge.com/en/news/288573903.md)
*2026-06-03T12:06:18.000Z*
> In Wednesday's pre-market session, several healthcare stocks showed significant movement. Gainers included Picard Medica

### [Relmada Therapeutics Q1 Earnings Call Highlights](https://longbridge.com/en/news/286182459.md)
*2026-05-13T02:06:18.000Z*
> Relmada Therapeutics (NASDAQ: RLMD) is on track to initiate its Phase 3 RESCUE program for NDV-01 in mid-2026, following

### [Transcript: Harrow Q1 2026 Earnings Conference Call](https://longbridge.com/en/news/286127404.md)
*2026-05-12T15:29:47.000Z*
> Harrow Inc (NASDAQ:HROW) reported Q1 2026 revenues of $44.2 million, with an adjusted EBITDA of -$12.7 million, impacted

### [Relmada Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286158030.md)
*2026-05-12T21:04:17.000Z*
### [Relmada Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286149867.md)
*2026-05-12T20:10:59.000Z*